Base Pair Bio receives SBIR Phase I Contract – “Development of Glycosylation-specific Research Aptamers”

9/13/2011. BioTex, Inc., the parent company of Ice Nine Biotechnologies has received a Phase I SBIR Phase I Contract of $150,000 from the National Institutes of Health, National Cancer Institute entitled, “Development of Glycosylation-specific Research Aptamers”.